Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
ADNOC Gas Targets Up to $4B Profit in 2026 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SEATTLE, Feb. 21, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2017 financial results after the close of trading on Wednesday, March 7, 2018. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 5389066. To listen to a live webcast, please visit the investor relations section of the company’s website at nanostring.com.
A replay of the call will be available beginning March 7, 2018 at 7:30pm ET through midnight on March 14, 2018. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 5389066. The webcast will also be available on the Company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,830 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
